IMB Dx is a precision oncology company focused on developing solutions for safe & accurate cancer diagnosis & monitoring. We created AlphaLiquid®, a minimally-invasive liquid biopsy method which requires only a single blood draw to detect cancer and monitor its progress. With AlphaLiquid®, we offer a comprehensive genomic profile of the tumor and matching therapies as well as clinical trial information. Since we began our research in 2014, our goal has remained the same: to make cancer diagnosis accessible and affordable to as many cancer patients as possible. For more information, please visit us at www.imbdx.com/eng/ or contact us at [email protected].
我們正在追蹤 IMBdx 的市場擴張
IMBdx 的國際擴張與競爭對手的比較
IMBdx你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 IMBdx你 | 0 | 0 | — | 0 | 0 |
IMBdx 첨단바이오 융합인재(AI전문가) 모집
查看招聘Seoul, South Korea · 3星期前
Global BD Manager
查看招聘Seoul, South Korea · 8個月前
Global Business Development Manager
查看招聘Seoul, South Korea · 8個月前
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
多家韓國公司公布2025年第二季度財務業績，包括Kiwoom證券、SOOP、GS建設等。多家公司宣布投資、合同和公司行動。
IMBdx的首次公開募股超額認購，認購保證金達10.7萬億韓元，吸引465,671名認購者，競爭比率為2654.2比1。
Teragen Bio 被選為 PAVE 項目的執行機構，開發個性化抗癌疫苗。與 NeoVax-K 聯盟合作，目標將預測準確率提高到 90% 以上。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 IMBdx 業務、市場及增長訊號的快速解答。
